Vyepti[®] recommended for approval in the EU by CHMP for the preventive treatment of migraine in adults
· Subject to final approval by the European Commission, Vyepti[®] (eptinezumab) will be the first intravenous (IV) treatment approved for migraine prevention in Europe. Valby, Denmark, November 12, 2021 - H. Lundbeck A/S (Lundbeck) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion and recommended granting a marketing authorization to Vyepti[®] (eptinezumab) in the European Union (EU) for the preventive treatment of migraine in adults who have at least 4 migraine days per month. Subject to final